APLT stock touches 52-week low at $0.54 amid sharp annual decline

Published 21/02/2025, 19:44
APLT stock touches 52-week low at $0.54 amid sharp annual decline

Applied Therapeutics Inc (NASDAQ:APLT) stock has plummeted to a 52-week low, trading at $0.54, with a market capitalization of just $63 million, as investors grapple with the company’s significant downturn over the past year. According to InvestingPro data, the stock shows signs of being slightly undervalued based on its Fair Value analysis. The biotechnology firm, which focuses on developing novel treatments in areas of high unmet medical need, has seen its stock price erode by an alarming 90.91% over the past six months. This stark decline reflects investor concerns and the challenges faced by the company in advancing its therapeutic pipeline amidst a competitive and rapidly evolving healthcare market. While the company maintains a strong balance sheet with more cash than debt, InvestingPro analysis reveals that three analysts have recently revised their earnings expectations downward. The 52-week low serves as a critical juncture for Applied Therapeutics, as it seeks to reassure stakeholders and potentially recalibrate its strategic approach to drug development and market positioning. For deeper insights into APLT’s financial health and future prospects, access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Applied Digital Corporation reported fiscal second quarter results that exceeded analyst expectations. The company achieved adjusted earnings per share of -$0.06, surpassing the analyst consensus of -$0.14. Revenue reached $63.9 million, marking a 51% year-over-year increase and slightly exceeding estimates of $63.39 million. The Cloud Services segment significantly contributed to this growth, with revenue rising 523% year-over-year to $27.7 million. Additionally, Applied Digital’s Data Center Hosting business generated $36.2 million in revenue for the quarter. The company also announced a $5 billion perpetual preferred equity financing facility with Macquarie Asset Management, aiming to strengthen its position as a leading HPC data center operator in the U.S.

In other developments, Applied Therapeutics, Inc. received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement. The company’s stock closed below the $1.00 minimum bid price for 30 consecutive business days. Applied Therapeutics has until August 6, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. If it fails to meet this requirement, the company may have the option to transfer its stock listing to the Nasdaq Capital Market for an additional 180-day compliance period. The company’s executive team is currently evaluating options to address the delisting risk.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.